|Stephen L. Eck, M.D., Ph.D|
Strategy & Development Committee
Nominating and Corporate Governance Committee
Stephen L. Eck, MD, PhD, age 61, joined the board of directors in March 2016. Since 2011 he has served as the Vice President, Oncology Medical Sciences of Astellas Pharma Global Development, a global pharmaceutical company. He is responsible for the design and conduct of domestic and international oncology clinical studies, which include the use of molecular testing for disease diagnosis and to monitor drug efficacy and safety.
From 2007 to 2011, Dr. Eck served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly, a global pharmaceutical company. There, he was responsible for the clinical pharmacology components of drug development, including both early phase clinical studies and late stage drug development studies. He was responsible for the Diagnostic and Experimental Medicines and laboratory for Experimental Medicine departments which designed, built and deployed novel clinical test platforms to be used in clinical studies. Before his tenure at Eli Lily, Dr. Eck led drug development teams at Pfizer from 2002 to 2007, including the Molecular Profiling Group and the Translational Medicine organization.
Prior to joining the pharmaceutic industry, Dr. Eck was a member of the faculty of the University of Pennsylvania School of Medicine, where he focused on Hematology and Oncology. He is a Fellow of the American Association for the Advancement of Science. He also serves on the Scientific Advisory Board of the ACGT Foundation, the Board of Trustees of the Keck Graduate Institute, the Board of Directors of the Central Pennsylvania Clinic, and on the Board of Directors of the Personalized Medicine Coalition. Dr. Eck holds a B.S. in Chemistry from Kalamazoo College, a Ph.D. in Chemistry from Harvard University and a M.D. in Medicine from the University of Mississippi.